150 related articles for article (PubMed ID: 11226552)
1. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
Keller M
Gen Hosp Psychiatry; 2001; 23(1):15-9. PubMed ID: 11226552
[TBL] [Abstract][Full Text] [Related]
2. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
3. Assessment of social functioning in depression.
Bosc M
Compr Psychiatry; 2000; 41(1):63-9. PubMed ID: 10646621
[TBL] [Abstract][Full Text] [Related]
4. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Dubini A; Bosc M; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
[TBL] [Abstract][Full Text] [Related]
5. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
Massana J; Möller HJ; Burrows GD; Montenegro RM
Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
Taner E; Demir EY; Cosar B
Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
Bosc M; Dubini A; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S57-70; discussion S71-3. PubMed ID: 9169311
[TBL] [Abstract][Full Text] [Related]
8. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Venditti LN; Arcelus A; Birnbaum H; Greenberg P; Barr CE; Rowland C; Williamson T
Int Clin Psychopharmacol; 2000 Sep; 15(5):279-89. PubMed ID: 10993130
[TBL] [Abstract][Full Text] [Related]
9. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
10. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Nelson JC; Portera L; Leon AC
J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
[TBL] [Abstract][Full Text] [Related]
11. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
[TBL] [Abstract][Full Text] [Related]
12. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
Healy D
Acta Psychiatr Scand Suppl; 2000; 402():45-51. PubMed ID: 10901159
[TBL] [Abstract][Full Text] [Related]
13. From symptoms to social functioning: differential effects of antidepressant therapy.
Kasper S
Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S27-31. PubMed ID: 10468326
[TBL] [Abstract][Full Text] [Related]
14. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana J
J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
[TBL] [Abstract][Full Text] [Related]
15. Predicting response: noradrenaline reuptake inhibition.
Montgomery SA
Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
[TBL] [Abstract][Full Text] [Related]
16. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
Clayton AH; Zajecka J; Ferguson JM; Filipiak-Reisner JK; Brown MT; Schwartz GE
Int Clin Psychopharmacol; 2003 May; 18(3):151-6. PubMed ID: 12702894
[TBL] [Abstract][Full Text] [Related]
17. Novel antidepressant strategies to optimize outcome.
J Clin Psychiatry; 2000 Sep; 61(9):686-96. PubMed ID: 11030494
[No Abstract] [Full Text] [Related]
18. Reboxetine: additional benefits to the depressed patient.
Montgomery SA
J Psychopharmacol; 1997; 11(4 Suppl):S9-15. PubMed ID: 9438228
[TBL] [Abstract][Full Text] [Related]
19. The need for new and better antidepressants: reboxetine a new option.
Dencker SJ
Acta Psychiatr Scand Suppl; 2000; 402():6-11. PubMed ID: 10901153
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of reboxetine in major depression.
Schatzberg AF
J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
